Add-on Peginterferon Alfa-2a significantly reduces HBsAg levels in chronic hepatitis B, HBeAg-negative, genotype D patients fully suppressed on nucleot(s)ide analogues treatment: HERMES Study Interim Analysis

被引：0
|
作者：
Lampertico, Pietro [1 ]
Brunetto, Maurizia R. [2 ,3 ]
Craxi, Antonio [4 ]
Gaeta, Giovanni B. [5 ]
Rizzetto, Mario [6 ]
Palmieri, Giulio [7 ]
Colombo, Massimo [1 ]
机构：
[1] Univ Milan, Div Gastroenterol & Hepatol, Osped Maggiore Policlin, Milan, Italy
[2] Univ Hosp Pisa, Reference Ctr Chron Liver Desease, Liver Unit, Pisa, Italy
[3] Univ Hosp Pisa, HCC Tuscany Reg, Pisa, Italy
[4] Univ Palermo, Di Bi MIS, Palermo, Italy
[5] Univ Naples 2, Dept Internal Med, Sect Infect Desease, Naples, Italy
[6] Univ Turin, Dept Gastroenterol, Turin, Italy
[7] Roche SpA, Monza, Italy
来源：
HEPATOLOGY | 2014年 / 60卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LB-31
引用
收藏
页码：1285A / 1286A
页数：2
相关论文
共 50 条
  • [1] ADD-ON PEGINTERFERON ALFA-2A SIGNIFICANTLY REDUCES HBSAG LEVELS IN CHRONIC HEPATITIS B, HBEAG-NEGATIVE, GENOTYPE D PATIENTS FULLY SUPPRESSED ON NUCLEOT(S)IDE ANALOGUES TREATMENT: HERMES STUDY INTERIM ANALYSIS
    Lampertico, P.
    Brunetto, M. R.
    Craxi, A.
    Gaeta, G. B.
    Rizzetto, M.
    Palmieri, G.
    Colombo, M.
    DIGESTIVE AND LIVER DISEASE, 2015, 47 : E28 - E28
  • [2] ADD-ON PEGINTERFERON ALFA-2A SIGNIFICANTLY REDUCES HBsAg LEVELS IN HBeAg-NEGATIVE, GENOTYPE D CHRONIC HEPATITIS B PATIENTS FULLY SUPPRESSED ON NUCLEOT(S)IDE ANALOGUE TREATMENT: THE HERMES STUDY
    Lampertico, P.
    Brunetto, M. R.
    Craxi, A.
    Gaeta, G. B.
    Rizzetto, M.
    Palmieri, G.
    Colombo, M.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S276 - S276
  • [3] ADD-ON PEGINTERFERON ALFA-2A SIGNIFICANTLY REDUCES HBSAG LEVELS IN HBEAG-NEGATIVE, GENOTYPE D CHRONIC HEPATITIS B PATIENTS FULLY SUPPRESSED ON NUCLEOT(S)IDE ANALOGUES TREATMENT: FINAL RESULTS OF THE HERMES STUDY
    Lampertico, P.
    Brunetto, M. R.
    Craxi, A.
    Gaeta, G. B.
    Rizzetto, M.
    Rozzi, A.
    Colombo, M.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S223 - S223
  • [4] MAINTENANCE PEGINTERFERON ALFA-2A TREATMENT REDUCES HBSAG LEVEL IN GENOTYPE D HBEAG-NEGATIVE INTERFERON-RESPONDERS (INTERIM RESULTS)
    Krastev, Z.
    Jelev, D.
    Ivanova, A.
    Antonov, K.
    Kosseva, O.
    Kotzev, I.
    Ivanova, I.
    Balabanska, R.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S292 - S292
  • [5] Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis
    Boglione, Lucio
    Cariti, Giuseppe
    Ghisetti, Valeria
    Burdino, Elisa
    Di Perri, Giovanni
    JOURNAL OF MEDICAL VIROLOGY, 2018, 90 (06) : 1047 - 1052
  • [6] INTRAHEPATIC HBSAG PREDICTS TREATMENT RESPONSE IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A AND ADEFOVIR: AN INTERIM ANALYSIS
    Takkenberg, Bart
    Terpstra, Valeska
    Zaaijer, Hans L.
    Weegink, Christine J.
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Beld, Marcel
    Reesink, Hendrik W.
    HEPATOLOGY, 2010, 52 (04) : 988A - 988A
  • [7] Early On-Treatment Prediction of Response to Peginterferon Alfa-2a for HBeAg-Negative Chronic Hepatitis B Using HBsAg and HBV DNA Levels
    Rijckborst, Vincent
    Hansen, Bettina E.
    Cakaloglu, Yilmaz
    Ferenci, Peter
    Tabak, Fehmi
    Akdogan, Meral
    Simon, Krzysztof
    Akarca, Ulus S.
    Flisiak, Robert
    Verhey, Elke
    Van Vuuren, Anneke J.
    Boucher, Charles A. B.
    ter Borg, Martijn J.
    Janssen, Harry L. A.
    HEPATOLOGY, 2010, 52 (02) : 454 - 461
  • [8] On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients
    Goulis, Ioannis
    Karatapanis, Stylianos
    Akriviadis, Evangelos
    Deutsch, Melanie
    Dalekos, George N.
    Raptopoulou-Gigi, Maria
    Mimidis, Konstantinos
    Germanidis, George
    Drakoulis, Christos
    Triantos, Christos
    Zintzaras, Elias
    Bakalos, Georgios
    Papatheodoridis, George
    LIVER INTERNATIONAL, 2015, 35 (05) : 1540 - 1548
  • [9] Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D
    Lampertico, Pietro
    Brunetto, Maurizia R.
    Craxi, Antonio
    Gaeta, Giovanni B.
    Rizzetto, Mario
    Rozzi, Antonella
    Colombo, Massimo
    Antonio, D.
    Andreone, P.
    Antonio, D.
    Brancaccio, G.
    Bronte, F.
    Bruzzone, L.
    Caccamo, G.
    Caccianotti, B.
    Calvaruso, V
    Chessa, L.
    Ciarallo, M.
    Coco, B.
    Colombatto, P.
    Cursaro, C.
    D'Aluisio, D.
    Demelia, L.
    Di Marco, V
    Dissegna, D.
    Invernizzi, F.
    Lenisa, I
    Lembo, T.
    Levrero, M.
    Marchese, V
    Mangia, G.
    Picciotto, A.
    Pierconti, S.
    Antonio, D.
    Raimondo, G.
    Rastelli, C.
    Rizzo, V
    Santantonio, T.
    Scuteri, A.
    Sorbello, O.
    Squadrito, G.
    Subic, M.
    Toniutto, P.
    Vukotic, R.
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (01) : 118 - 125
  • [10] BASELINE HBSAG LEVELS PREDICT HBSAG LOSS IN HBEAG NEGATIVE BUT NOT IN HBEAG POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA): AN INTERIM ANALYSIS
    Takkenberg, Bart
    Zaaijer, Hans L.
    de Niet, Annikki
    Weegink, Christine J.
    Terpstra, Valeska
    Koot, Maarten
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Janssen, Harry L.
    Beld, Marcel
    Reesink, Hendrik W.
    HEPATOLOGY, 2009, 50 (04) : 536A - 537A
12345